Chondroitin Sulfate Proteoglycan and its Degradation Products in CNS Repair

Advances in Pharmacology

Volumn 53, Issue , 2006, Pages 357-374

  Rolls, Asya ^a   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOCHONDROITIN SULFATE;

ANGIOGENESIS; ANIMAL; BRAIN; CELL SURVIVAL; HUMAN; IMMUNITY; NERVE REGENERATION; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

ANIMALS; BRAIN; CELL SURVIVAL; HUMANS; IMMUNITY; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE REGENERATION; PROTEOCHONDROITIN SULFATES; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 33846126628     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)53017-5     Document Type: Review

References (86)

1. Aoyama E., Yoshihara R., Tai A., Yamamoto I., and Gohda E. PKC- and PI3K-dependent but ERK-independent proliferation of murine splenic B cells stimulated by chondroitin sulfate B. Immunol. Lett. 99 (2005) 80-84
2. Ariel A., Hershkoviz R., Avron A., Franitza S., Hardan I., Cahalon L., Fridkin M., and Lider O. IL-2 induces T cell adherence to extracellular matrix: Inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. J. Immunol. 161 (1998) 2465-2472
3. Asher R.A., Morgenstern D.A., Shearer M.C., Adcock K.H., Pesheva P., and Fawcett J.W. Versican is upregulated in CNS injury and is a produci of oligodendrocyte lineage cells. J. Neurosci. 22 (2002) 2225-2236
4. Asher R.A., Morgenstern D.A., Fidler P.S., Adcock K.H., Oohira A., Braistead J.E., Levine J.M., Margolis R.U., Rogers J.H., and Fawcett J.W. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J. Neurosci. 20 (2000) 2427-2438
5. Bakalash S., Rolls A., Cahalon L., and Chwartz M. Controlling inflammation and neurodegeneration: The dual action of chondroitin sulfate proteoglycan degradation product. Invest. Ophthalmol. Vis. Sci. 46 (2005) E-Abstract 1289.
6. Bradbury E.J., Moon L.D., Popat R.J., King V.R., Bennett G.S., Palei P.N., Fawcett J.W., and McMahon S.B. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416 (2002) 636-640
7. Brittis P.A., Canning D.R., and Silver J. Chondroitin sulfate as a regulator of neuronal patterning in the retina. Science 255 (1992) 733-736
8. Butovsky O., Talpalar A.E., Ben-Yaakov K., and Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell Neurosci. 29 3 (2005) 381-393
9. Cahalon L., Lider O., Schor H., Avron A., Gilat D., Hershkoviz R., Margalit R., Eshel A., Shoseyev O., and Cohen I.R. Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents. Int. Immunol. 9 (1997) 1517-1522
10. Chau C.H., Shum D.K., Li H., Pei J., Lui Y.Y., Wirthlin L., Chan Y.S., and Xu X.M. Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded guidance channels after spinal cord injury. FASEB J. 18 (2004) 194-196
11. Chen Z.J., Negra M., Levine A., Ughrin Y., and Levine J.M. Oligodendrocyte precursor cells: Reactive cells that inhibit axon growth and regeneration. J. Neurocytol. 31 (2002) 481-495
12. Delfino D.V., Patrene K.D., DeLeo A.B., DeLeo R., Herberman R.B., and Boggs S.S. Role of CD44 in the development of natural killer cells from precursore in long-term cultures of mouse bone marrow. J. Immunol. 152 (1994) 5171-5179
13. Denholm E.M., Lin Y.Q., and Silver P.J. Anti-tumor activities of chondroitinase AC and chondroitinase B: Inhibition of angiogenesis, proliferation and invasion. Eur. J. Pharmacol. 416 (2001) 213-221
14. Dergham P., Ellezam B., Essagian C., Avedissian H., Lubell W.D., and McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22 (2002) 6570-6577
15. Domeniconi M., and Filbin M.T. Overcoming inhibitors in myelin to promote axonal regeneration. J. Neurol. Sci. 233 (2005) 43-47
16. Dou C.L., and Levine J.M. Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J. Neurosci. 14 (1994) 7616-7628
17. Fitch M.T., and Silver J. Activated macrophages and the blood-brain barrier: Inflammation after CNS injury leads to increases in putative inhibitory molecules. Exp. Neurol. 148 (1997) 587-603
18. Fouad K., Dietz V., and Schwab M.E. Improving axonal growth and functional recovery after experimental spinal cord injury by neutralizing myelin associated inhibitors. Brain Res. Rev. 36 (2001) 204-212
19. Fournier A.E., GrandPre T., Gould G., Wang X., and Strittmatter S.M. Nogo and the Nogo-66 receptor. Prog. Brain Res. 137 (2002) 361-369
20. Friedlander D.R., Milev P., Karthikeyan L., Margolis R.K., Margolis R.U., and Grumet M. The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/Ll/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J. Cell Biol. 125 (1994) 669-680
21. Garnier P., Gibbs R.V., and Rider C.C. A role for chondroitin sulphate B in the activity of interleukin 12 in stimulating gamma-interferon secretion. Immunol. Lett. 85 (2003) 53-58
22. Grados-Munro E.M., and Fournier A.E. Myelin-associated inhibitors of axon regeneration. J. Neurosci. Res. 74 (2003) 479-485
23. Grimpe B., and Silver J. A novel DNA enzyme reduces glycosaminoglycan chains in the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate beyond lesions in the spinal cord. J. Neurosci. 24 (2004) 1393-1397
24. Gupta-Bansal R., Frederickson R.C., and Brunden K.R. Proteoglycan-mediated inhibition of A beta proteolysis: A potential cause of senile plaque accumulation. J. Biol. Chem. 270 (1995) 18666-18671
25. He Z., and Koprivica V. The Nogo signaling pathway for regeneration block. Annu. Rev. Neurosci. 27 (2004) 341-368
26. Horn K.P., Steinmetz M.P., Tom V.J., and Miller J.H. Soluble macrophages-derived factors digest proteoglycan and enhance neurite outgrowth in an in vitro model of the glial scar. Society for Neuroscience, Program No. 43.17 (2004)
27. Huxlin K.R., Carr R., Schulz M., Sefton A.J., and Bennett M.R. Trophic effect of collicular proteoglycan on neonatal rat retinal ganglion cells in situ. Brain. Res. Dev. 84 (1995) 77-88
28. Huxlin K.R., Dreher B., Schulz M., Sefton A.J., and Bennett M.R. Effect of collicular proteoglycan on the survival of adult rat retinal ganglion cells following axotomy. Eur. J. Neurosci. 7 (1995) 96-107
29. Jain A., Brady-Kalnay S.M., and Bellamkonda R.V. Modulation of Rho GTPase activity alleviates chondroitin sulfate proteoglycan-dependent inhibition of neurite extension. J. Neurosci. Res. 77 (2004) 299-307
30. Jones L.L., and Tuszynski M.H. Spinal cord injury elicits expression of keratan sulfate proteoglycans by macrophages, reactive microglia, and oligodendrocyte progenitors. J. Neurosci. 22 (2002) 4611-4624
31. Jones L.L., Margolis R.U., and Tuszynski M.H. The chondroitin sulfate proteoglycans neurocan, brevican, phosphocan, and versican are differentially regulated following spinal cord injury. Exp. Neurol. 182 2 (2003) 399-411
32. Kappler J., Junghans U., Koops A., Stichel C.C., Hausser H.J., Kresse H., and Muller H.W. Chondroitin/dermatan sulphate promotes the survival of neurons from rat embryonic neocortex. Eur. J. Neurosci. 9 (1997) 306-318
33. Kastin A.J., and Fan W. Targeting neurite growth inhibitors to induce CNS regeneration. Curr. Pharm. Des. 11 (2005) 1247-1253
34. Kipnis J., Yoles E., Schori H., Hauben E., Shaked I., and Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J. Neurosci. 21 13 (2001) 4564-4571
35. Kipnis J., and Schwartz M. Controlled autoimmunity in CNS maintenance and repair: Naturally occurring CD4+ CD25+ regulatory T-cells at the crossroads of health and disease. Neuromolecular Med. 7 3 (2005) 197-206
36. Koops A., Kappler J., Junghans U., Kuhn G., Kresse H., and Muller H.W. Cultured astrocytes express biglycan, a chondroitin/dermatan sulfate proteoglycan supporting the survival of neocortical neurons. Brain Res. Mol. 41 (1996) 65-73
37. Krekoski C.A., Neubauer D., Zuo J., and Muir D. Axonal regeneration into acellular nerve grafts is enhanced by degradation of chondroitin sulfate proteoglycan. J. Neurosci. 21 (2001) 6206-6213
38. Kwakkenbos M.J., Pouwels W., Matmati M., Stacey M., Lin H.H., Gordon S., van Lier R.A., and Hamann J. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J. Leukoc. Biol. 77 (2005) 112-119
39. Levine J.M. Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury. J. Neurosci. 14 (1994) 4716-4730
40. Lider O., Mekori Y.A., Miller T., Bar-Tana R., Vlodavsky I., Baharav E., Cohen I.R., and Naparstek Y. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 20 (1990) 493-499
41. MacDermott R.P., Schmidt R.E., Caulfield J.P., Hein A., Bartley G.T., Ritz J., Schlossman S.F., Austen K.F., and Stevens R.L. Proteoglycans in cell-mediated cytotoxicity: Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J. Exp. Med. 162 (1985) 1771-1787
42. Maeda N., and Noda M. 6B4 proteoglycan/phosphacan is a repulsive substratum but promotes morphological differentiation of cortical neurons. Development 122 (1996) 647-658
43. Maeda N., Matsui F., and Oohira A. A chondroitin sulfate proteoglycan that is developmentally regulated in the cerebellar mossy fìber System. Dev. Biol. 151 (1992) 564-574
44. Makatsori E., Lamari F.N., Theocharis A.D., Anagnostides S., Hjerpe A., Tsegenidis T., and Karamanos N.K. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res. 23 (2003) 3303-3309
45. Matsui F., and Oohira A. Proteoglycans and injury of the central nervous system. Congenit. Anom. (Kyoto) 44 (2004) 181-188
46. McKeon R.J., Schreiber R.C., Rudge J.S., and Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci. 11 (1991) 3398-3411
47. Monnier P.P., Sierra A., Schwab J.M., Henke-Fahle S., and Mueller B.K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 22 (2003) 319-330
48. Moon L.D., Asher R.A., and Fawcett J.W. Limited growth of severed CNS axons after treatment of adult rat brain with hyaluronidase. J. Neurosci. Res. 71 (2003) 23-37
49. Moon L.D., Asher R.A., Rhodes K.E., and Fawcett J.W. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat. Neurosci. 4 (2001) 465-466
50. Nadanaka S., Clement A., Masayama K., Faissner A., and Sugahara K. Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity. J. Biol. Chem. 273 (1998) 3296-3307
51. Nichel K.A., Schulz M.W., and Bennett M.R. Nitric oxide-mediated death of cultured neonatal retinal ganglion cells: Neuroprotective propertìes of glutamate and chondroitin sulfate proteoglycan. Brain Res. 697 (1995) 1-16
52. Oohira A., Katoh-Semba R., Watanabe E., and Matsui F. Brain development and multiple molecular species of proteoglycan. Neurosci. Res. 20 (1994) 195-207
53. Pindzola R.R., Doller C., and Silver J. Putative inhibitory extracellular matrix molecules at the dorsal root entry zone of the spinal cord during development and after root and sciatic nerve lesions. Dev. Biol. 156 (1993) 34-48
54. Pizzorusso T., Medini P., Berardi N., Chierzi S., Fawcett J.W., and Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. Science 298 (2002) 1248-1251
55. Pratibha V., and Gupta P.D. Cutaneous wound healing: Significance of proteoglycans in scar formation. Curr. Sci. 78 6 (2000)
56. Properzi F., Asher R.A., and Fawcett J.W. Chondroitin sulphate proteoglycans in the central nervous system: Changes and synthesis after injury. Biochem. Soc. Trans. 31 (2003) 335-336
57. Rachmilewitz J., and Tykocinski M.L. Differential effects of chondroitin sulfates A and B on monocyte and B-cell activation: Evidence for B-cell activation via a CD44-dependent pathway. Blood 92 (1998) 223-229
58. Ramsden L., and Rider C.C. Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans. Eur. J. Immunol. 22 (1992) 3027-3031
59. Roitbak T., and Sykova E. Diffusion barriers evoked in the rat cortex by reactive astrogliosis. Glia 28 (1999) 40-48
60. Rolls A., Avidan H., Cahalon L., Schori H., Bakalash S., and Lider O. Chondroitin sulfate proteoglycan a SOS molecule in CNS repair. Society for Neuroscience, Program No. 24.5.2004 (2004)
61. Rolls A., Avidan H., Cahalon L., Schori H., Bakalash S., Litvak V., Lev S., Lider O., and Schwartz M. A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur. J. Neurosci. 20 (2004) 1973-1983
62. Rolls A., Cahalon L., Bakalash S., Avidan H., Lider O., and Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J. 20 3 (2006) 547-549
63. Ruoslahti E., and Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 64 (1991) 867-869
64. Sakai S., Akiyama H., Harikai N., Toyoda H., Toida T., Maitani T., and Imanari T. Effect of chondroitin sulfate on murine splenocytes sensitized with ovalbumin. Immunol. Lett. 84 (2002) 211-216
65. Schmalfeldt M., Bandtlow C.E., Dours-Zimmermann M.T., Winterhalter K.H., and Zimmermann D.R. Brain derived versican V2 is a potent inhibitor of axonal growth. J. Cell Sci. 113 (2000) 807-816
66. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A., and Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate toxicity and ocular hypertension: Implications for glaucoma. Proc. Natl. Acad. Sci. USA 98 6 (2001) 3398-3403
67. Schwartz N.B., and Domowicz M. Proteoglycans in brain development. Glycoconj. J. 21 (2004) 329-341
68. Shaked I., Tchoresh D., Gersner R., Meiri G., Mordechai S., Xiao X., Kart R.P., and Schwartz M. Protective autoimmunity: Interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J. Neurochem. 92 (2005) 997-1009
69. Sivasankaran R., Pei J., Wang K.C., Zhang Y.P., Shields C.B., Xu X.M., and He Z. PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration. Nat. Neurosci. 7 (2004) 261-268
70. Smith-Thomas L.C., Fok-Seang J., Stevens J., Du J.S., Muir E., Faissner A., Geller H.M., Rogers J.H., and Fawcett J.W. An inhibitor of neurite outgrowth produced by astrocytes. J. Cell Sci. 107 (1994) 1687-1695
71. Snow D.M., Watanabe M., Letourneau P.C., and Silver J. A chondroitin sulfate proteoglycan may influence the direction of retinal ganglion cell outgrowth. Development 113 (1991) 1473-1485
72. Sorensson J., Bjornson A., Ohlson M., Ballermann B.J., and Haraldsson B. Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am. J. Physiol. Renal Physiol. 284 (2003) F373-F380
73. Steindler D.A., O'Brien T.F., Laywell E., Harrington K., Faissner A., and Schachner M. Boundaries during normal and abnormal brain development: In vivo and in vitro studies of glia and glycoconjugates. Exp. Neurol. 109 (1990) 35-56
74. Sykova E. Glial diffusion barriers during aging and pathological states. Prog. Brain. Res. 132 (2001) 339-363
75. Teng F.Y., and Tang B.L. Nogo signaling and non-physical injury-induced nervous system pathology. J. Neurosci. Res. 79 (2005) 273-278
76. Tropea D., Calco M., and Maffei L. Synergistic effects of brain-derived neurotrophic factor and chondroitinase ABC on retinal fiber sprouting after denervation of the superici colliculus in aduli rats. J. Neurosci. 23 (2003) 7034-7044
77. Tufvesson E., and Westergren-Thorsson G. Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration. J. Cell Sci. 116 (2003) 4857-4864
78. Villena J., and Brandan E. Dermatan sulfate exerts an enhanced growth factor response on skeletal muscle satellite cell proliferation and migration. J. Cell. Physiol. 198 (2004) 169-178
79. Wegrowski Y., Paltot V., Gillery P., Kalis B., Randoux A., and Maquart F.X. Stimulation of sulphated glycosaminoglycan and decorin production in adult dermal fibroblasts by recombinant human interleukin-4. Biochem. J. 307 (1995) 673-678
80. Woods A.G., Cribbs D.H., Whittemore E.R., and Cotman C.W. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid (25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res. 697 (1995) 53-62
81. Wrenshall L.E., Stevens R.B., Cerra F.B., and Platt J.L. Modulation of macrophage and B cell function by glycosaminoglycans. J. Leukoc. Biol. 66 (1999) 391-400
82. Yamada H., Predette B., Shitara K., Hagihara K., Miura R., Ranscht B., Stallcup W.B., and Yamaguchi Y. The brain chondroitin sulfate proteoglycan brevican associates with astrocytes ensheathing cerebellar glomeruli and inhibits neurite outgrowth from granule neurons. J. Neurosci. 17 (1997) 7784-7795
83. Yamaguchi Y., Mann D.M., and Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346 (1990) 281-284
84. Yang R., Yan Z., Chen F., Hansson G.K., and Kiessling R. Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity. Scand. J. Immunol. 55 (2002) 2-13
85. Yick L.W., Wu W., So K.F., Yip H.K., and Shum D.K. Chondroitinase ABC promotes axonal regeneration of Clarke's neurons after spinal cord injury. Neuroreport 11 (2000) 1063-1067
86. Zuo J., Neubauer D., Graham J., Krekoski C.A., Ferguson T.A., and Muir D. Regeneration of axons after nerve transection repair is enhanced by degradation of chondroitin sulfate proteoglycan. Exp. Neurol. 176 1 (2002) 221-228